GE HealthCare Technologies Inc. · NASDAQ:GEHC

GE HealthCare Technologies — Technical Presentation (March 2023)

27 slides from GE HealthCare Technologies's technical presentation, March 2023

  1. Slide 1: Cerianna Case Review

    Cerianna Case Review © 2023 GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

  2. Slide 2: Important Safety Information

    Important Safety Information INDICATIONS AND USAGE CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. Limitations of Use Tissue biop

  3. Slide 3: By detecting ER status, Cerianna may help provide confidence in therapy selection

    By detecting ER status, Cerianna may help provide confidence in therapy selection when considering first or second line endocrine therapy in the metastatic setting © 2023 GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

  4. Slide 4: Case #1

    Case #1: • 57-year-old female who presented in June of 2020 with locally advanced disease • Pathology: Invasive lobular carcinoma, ER+ 95%, Ki67 15-20% • She was treated with neoadjuvant chemotherapy; however, subsequent scans revealed metastatic disease in lymph nodes and bone • She was initiated o

  5. Slide 5: Cerianna PET/CT vs FDG PET/CT

    Cerianna + PET/CT + + FDG PET/CT Right Axillary Lymph T12 Bone Window Right Sacrum Node CT=computed tomography, FDG=Fluorodeoxyglucose, +=positive, -=negative, PET = Positron emission tomography Images courtesy of Dr Judy Rose, RadNet © 2023 GE HealthCare. GE is a trademark of General Electric Compa

  6. Slide 6: Case #2

    Case #2: • 83-year-old female with newly diagnosed T4N1 right breast cancer • Pathology: – Right breast primary revealed ER positive breast carcinoma – Right axillary node positive for metastatic disease, ER negative • Staging FDG PET/CT scan demonstrated a suspicious rib lesion (in addition to righ

  7. Slide 7: Right breast primary lesion, axillary node, rib lesion

    Right breast primary lesion Right axillary node Right rib lesion CT CT CT 18F-FDG 18F-FDG 18F-FDG Cerianna Cerianna Cerianna CT = Computed Tomography, FDG = Fluorodeoxyglucose, + = Positive, - = Negative Images courtesy of Saint Louis Hospital © 2023 GE HealthCare. GE is a trademark of General Elect

  8. Slide 8: Cerianna and FDG results show agreement, indicating ER+ disease

    Cerianna and FDG results show agreement, indicating ER+ disease Cerianna F18-FDG FDG = Fluorodeoxyglucose, ER = estrogen receptor, + = positive Images courtesy of Saint Louis Hospital © 2023 GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

  9. Slide 9: Cerianna may help detect ER status when other imaging tests are equivocal

    Cerianna may help detect ER status in lesions when other imaging tests are equivocal or suspicious © 2023 GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

  10. Slide 10: Case #1

    Case #1: • 67-year-old female with family history of breast cancer in her mother presented with new drooping in her right eyelid March 2022 • Patient was seen by an ophthalmologist, MRI ordered – Results showed a right superior enhancing soft tissue mass in her right orbit • Treated for possible inf

  11. Slide 11: Imaging workup and clinician question

    • Imaging workup initiated with a breast mammogram and FDG PET scan • Mammogram showed mild nipple retraction, no distinct mass • PET FDG was negative • Breast MRI revealed abnormal skin thickening with large area of non-mass enhancement measuring 7.1 cm in the right lateral breast • Biopsy of the r

  12. Slide 12: MRI: Head/Orbit

    MRI: Head/Orbit MRI: Head/Orbit MRI = Magnetic Resonance Imaging Images Courtesy of Dr. Joseph Mock, Blue Ridge Cancer Center © 2023 GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

  13. Slide 13: FDG PET/CT: Negative

    FDG PET/CT: Negative FDG PET/CT: Negative FDG = Fluorodeoxyglucose, CT = Computed Tomography, PET = Positron emission tomography Images Courtesy of Dr. Joseph Mock, Blue Ridge Cancer Center © 2023 GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

  14. Slide 14: Cerianna PET positive for ER+ metastatic disease

    Cerianna PET Cerianna PET positive for ER+ metastatic disease • ER-positive right breast lesion, right axillary node, left internal mammary node • ER-positive left cervical node • ER-positive right orbital lesion • ER-positive skull metastasis PET = Positron emission tomography Images Courtesy of Dr

  15. Slide 15: Case #2

    Case #2: • 60-year-old female, experienced worsening severe neck pain in November 2019; presented to local emergency room • MRI, CT imaging revealed a metastatic lesion C2 vertebra • Patient underwent emergency laminectomy (C1-C3) by neurosurgeon, pathology revealed breast adenocarcinoma primary, ER

  16. Slide 16: Cerianna PET/CT and FDG PET/CT, Cervical Spine Axial

    Cerianna PET/CT FDG PET/CT + + Cervical Spine Axial Bone Window Cervical Spine Axial Bone Window CT = computed tomography, FDG = fluorodeoxyglucose, + = positive, PET = Positron emission tomography Images Courtesy of Dr. Judy Rose, RadNet © 2023 GE HealthCare. GE is a trademark of General Electric C

  17. Slide 17: Cerianna PET/CT and FDG PET/CT, Cervical Spine Sagittal

    Cerianna PET/CT FDG PET/CT + Cervical Spine Sagittal Bone Window Cervical Spine Sagittal Bone Window CT = Computed Tomography, FDG = Fluorodeoxyglucose, + = Positive, - = Negative, PET = Positron emission tomography Images courtesy of Dr. Judy Rose, RadNet © 2023 GE HealthCare. GE is a trademark of

  18. Slide 18: Cerianna may help assess ER status in lesions difficult or dangerous to biopsy

    Cerianna may help enable the assessment of ER status in lesions that are difficult or dangerous to biopsy, or biopsy is non-diagnostic © 2023 GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

  19. Slide 19: Case #1

    Case #1: • 43-year-old female, diagnosed with right-sided breast cancer after self- palpation and ultrasound-guided biopsy 5/2022 showing invasive ductal carcinoma, ER+ 100%, Ki67 20% • Ultrasound revealed a 3-centimeter axillary lymph node • Staging FDG-PET scan revealed the primary tumor, limited

  20. Slide 20: Cerianna and FDG: Breast, Satellite Lesions, Axillary Node

    Right Breast Primary 3 Satellite Breast Lesions Right Axillary Lymph Node + + Cerianna + PET/CT + + FDG + PET/CT Images Courtesy of Dr. Judy Rose, RadNet Chest Wall Axial Soft Tissue Window FDG = Fluorodeoxyglucose, + = Positive, CT = Computed Tomography, PET = Positron emission tomography © 2023 GE

  21. Slide 21: Cerianna and FDG: L5 Metastasis, Internal Mammary Node

    L5 Metastasis Right Internal Mammary Lymph Node Cerianna PET/CT + + FDG PET/CT + + Sagittal Bone Window Axial Soft Tissue Window FDG = Fluorodeoxyglucose, FES = Fluoroestradiol, CT = Computed Tomography, L = Lumbar, + = Positive, PET = Positron emission tomography Images Courtesy of Dr. Judy Rose, R

  22. Slide 22: Case #2

    Case #2: • 59-year-old female with history of left breast invasive ductal carcinoma, T2N1, ER/PR positive, HER2 negative • Patient treated with neoadjuvant chemotherapy, conservative surgery, radiation and adjuvant endocrine therapy • 2 years post adjuvant therapy, she presented with a new pleural e

  23. Slide 23: 18F-FDG and Cerianna images

    18F-FDG Cerianna FDG = Fluorodeoxyglucose Images Courtesy of Tenon Hospital (France), FES used in this study is not equivalent to the FDA-approved Cerianna formulation. © 2023 GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

  24. Slide 24: Important Safety Information

    Important Safety Information INDICATIONS AND USAGE: CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)- positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. Limitations of Use: Tissue b

  25. Slide 25: Important Safety Information

    Important Safety Information Radiation Risks Diagnostic radiopharmaceuticals, including CERIANNA, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe drug handling and patient preparation procedures (including adequate hydration

  26. Slide 26: Important Safety Information

    Important Safety Information Lactation Risk Summary • There are no data on the presence of fluoroestradiol F 18 in human milk, or its effects on the breastfed infant or milk production. Lactation studies have not been conducted in animals. Advise a lactating woman to avoid breastfeeding for 4 hours

  27. Slide 27: Thank you

    Thank you © 2023 GE HealthCare Cerianna is a trademark of GE HealthCare. GE is a trademark of General Electric Company used under trademark license March 2023 JB07967US © 2023 GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

GE HealthCare — Technical Presentation (March 2023) on 6ix